Literature DB >> 28247660

[The incidence of acute urinary retention as an indicator of the quality of care for patients with benign prostatic hyperplasia].

O I Apolikhin1, A V Sivkov1, E K Yanenko1, M I Katibov1, O V Zolotukhin2,3, I A Shaderkin1, M Yu Prosyannikov1, D A Voitko1, A A Tsoi1, N A Galiev1, Yu V Kastrikin1.   

Abstract

AIM: To evaluate the incidence of acute urinary retention as an indicator of the quality of care for patients with benign prostatic hyperplasia by the example of "Urology" Program implemented in the Voronezh region.
MATERIALS AND METHODS: As part of the program "Urology", the incidence of AUR was used as an indicator of quality of care for patients with BPH. Urological health care for patients with BPH was provided within a three-stage model. For each of the stages standardized packages of detailed methodological materials, including regional standards were developed.
RESULTS: Over the 3 years of the program (2011-2013) questionnaire survey was conducted among 762 937 men 50-75 years old with 85.3-88.1% annual coverage of respondents. Over the past three years (2009-2012) there was consistent and statistically significant (p<0.05) decrease (from 11.27 to 1.5%) in the proportion of hospitalizations for AUR reaching a "plateau" (p>0.05) in 2012-2013. There was a significant correlation of AUR with the main indicators of effectiveness of BPH treatment: the structure of morbidity (prevalence of early BPH forms - groups 1 and 2), the number of surgical interventions, the frequency of complications (including surgical), general and specific costs for diagnosis and treatment of BPH.
CONCLUSIONS: Acute urinary retention may be regarded as an integral indicator of the quality of care for patients with BPH.

Entities:  

Keywords:  AUR; BPH; Urology Service of Voronezh region; program "Urology"; prostate adenoma; urinary retention

Mesh:

Year:  2016        PMID: 28247660

Source DB:  PubMed          Journal:  Urologiia        ISSN: 1728-2985


  1 in total

1.  Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride.

Authors:  Kirill V Kosilov; Irina G Kuzina; Vladimir Kuznetsov; Ekaterina K Kosilova
Journal:  Prostate Int       Date:  2020-02-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.